

JUL 28 2005

July 2005

## Appendix A: 510(K) Summary

---

K051973

### Submitter

Medtronic, Inc.  
710 Medtronic Parkway NE  
Minneapolis, MN 55432

Contact: Paula Cordero, Regulatory Affairs Specialist

Telephone: (763) 505-0238

Fax: (763) 505-0258

E-Mail: [paula.cordero@medtronic.com](mailto:paula.cordero@medtronic.com)

Date Prepared: July 1<sup>st</sup>, 2005

### Name of Device

Trade Name: Medtronic Model 3873 1 x 8 and Model 3874  
1 x 8 Compact Test Stimulation Leads

Common Name: Trialing Leads

Classification: Class II

Product Code: GZB

### Predicate Devices

The predicate device for the Medtronic Model 3873 1 x 8 Test Stimulation Leads and the Model 3874 1 x 8 Compact Test Stimulation Leads is the currently available Model 3862 Verify Temporary Screening Lead.

### Device Description

The Model 3873 1 x 8 and the Model 3874 1 x 8 Compact are test stimulation lead kits. A test stimulation lead is a thin wire covered by an insulative coating, which is intended to be connected to a screening cable and an external neurostimulator (ENS). The lead has small metal electrodes near its tip through which the ENS delivers electrical stimulation to an area where pain signals will be blocked.

### Intended Use

The Model 3873 1 x 8 and Model 3874 1 x 8 Compact Test Stimulation Leads are indicated as an aid in the management of chronic, intractable, unilateral or bilateral pain associated with the following:

- Failed Back Syndrome or Low Back Syndrome or Failed Back;

- Radicular Pain Syndrome or Radiculopathies resulting in pain secondary to Failed Back Syndrome;
- Post Laminectomy Pain;
- Unsuccessful Disk Surgery;
- Degenerative Disk Disease (DDD/ Herniated pain refractory to conservative and surgical interventions;
- Peripheral Causalgia;
- Epidural Fibrosis;
- Arachnoiditis or Lumbar Adhesive Arachnoiditis;
- Complex Regional Pain Syndrome (CRPS) or Reflex Sympathetic Dystrophy (RSD) or Causalgia; and,
- Multiple Back Surgeries

**Additional Contraindication:** The Medtronic Models 3873 1 x 8 and the 3874 1 x 8 Compact Test Stimulation Leads are contraindicated for long-term implantation. The lead **MUST BE REMOVED** within ten (10) days of implant.

### Summary of Studies

In Vitro testing was performed to support substantial equivalence to the predicate device. The Model 3873 1 x 8 and the Model 3874 1 x 8 Compact Test Stimulation Lead Kits met all specified design and performance requirements.

### Sterilization

The Medtronic Model 3873 1 x 8 and the Model 3874 1 x 8 Compact Test Stimulation Lead Kits are labeled STERILE. The Model 3873 1 x 8 and the Model 3874 1 x 8 Compact Test Stimulation Lead Kits will be sterilized using the same 100% Ethylene Oxide (EtO) sterilization process as the predicate device.

### Biocompatibility

All device materials / components were assessed for biocompatibility consistent with ISO- 10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing". All materials were found to be biocompatible and in compliance to ISO 10993-1.

### Conclusion

Through data and information presented, as well as similarity to legally marketed devices, Medtronic, Inc. considers the Model 3873 1 x 8 and the Model 3874 1 x 8 Compact Test Stimulation Lead Kits to be substantially equivalent to legally marketed predicate devices.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 28 2005

Ms. Paula Cordero  
Regulatory Affairs Specialist  
Medtronic, Inc., Neurological Division  
710 Medtronic Parkway NE  
Minneapolis, Minnesota 55432-5604

Re: K051773

Trade/Device Name: Medtronic® Model 38731 x 8 and Model 38741 x 8 Compact Test  
Stimulation Leads

Regulation Number: 21 CFR 882.5880

Regulation Name: Implanted spinal cord stimulator for pain relief

Regulatory Class: II

Product Code: GZB

Dated: June 30, 2005

Received: July 5, 2005

Dear Ms. Cordero:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", followed by a horizontal line.

Mark N. Melkerson  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## 4. Indications for Use

---

510(k) Number (if known): N/A

**Device Name:** Medtronic® Model 3873 1 x 8 and Model 3874 1 x 8 Compact Test Stimulation Leads

**Indications For Use:** The Model 3873 1 x 8 and Model 3874 1 x 8 Compact Test Stimulation Leads are indicated as an aid in the management of chronic, intractable, unilateral or bilateral pain associated with the following:

- Failed Back Syndrome or Low Back Syndrome or Failed Back;
- Radicular Pain Syndrome or Radiculopathies resulting in pain secondary to Failed Back Syndrome;
- Post Laminectomy Pain;
- Unsuccessful Disk Surgery;
- Degenerative Disk Disease (DDD/ Herniated pain refractory to conservative and surgical interventions;
- Peripheral Causalgia;
- Epidural Fibrosis;
- Arachnoiditis or Lumbar Adhesive Arachnoiditis;
- Complex Regional Pain Syndrome (CRPS) or Reflex Sympathetic Dystrophy (RSD) or Causalgia; and,
- Multiple Back Surgeries

**Additional Contraindication:** The Medtronic Models 3873 1 x 8 and the 3874 1 x 8 Compact Test Stimulation Leads are contraindicated for long-term implantation. The lead **MUST BE REMOVED** within ten (10) days of implant.


Prescription Use   X    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

  
Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

Number \_\_\_\_\_

7  
K051773